{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:01:27Z","timestamp":1783663287366,"version":"3.55.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2025\/R\/1447"],"award-info":[{"award-number":["PSAU\/2025\/R\/1447"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105206","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:19:27Z","timestamp":1771226367000},"page":"105206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mapping the molecular landscape of glioblastoma: Pathogenesis, therapeutic targets and bioactive interventions"],"prefix":"10.1016","volume":"221","author":[{"given":"Ankita","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humood Al","family":"Shmrany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3892\/ol.2016.4955","article-title":"Role of Yes-associated protein in cancer: an update","volume":"12","author":"Abylkassov","year":"2016","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40478-023-01605-x","article-title":"On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells","volume":"11","author":"Ah-Pine","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105206_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/biotech14020028","article-title":"Matrix metalloproteinases in glioma: drivers of invasion and therapeutic targets","volume":"14","author":"Aitchison","year":"2025","journal-title":"BioTech"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105206_bib4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/cancers11070978","article-title":"Are integrins still practicable targets for anti-cancer therapy?","volume":"11","author":"Alday-Parejo","year":"2019","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105206_bib5","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.3390\/cancers13225799","article-title":"Tyrosine kinase inhibitors in adult glioblastoma: an (un) closed chapter?","volume":"13","author":"Aldaz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105206_bib6","article-title":"DNA hydrogels for glioblastoma: programmable, tumor-responsive nanocarriers for precision therapy and theranostics","author":"Alizadeh","year":"2025","journal-title":"Cancer Nanotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib7","doi-asserted-by":"crossref","first-page":"NS20180201","DOI":"10.1042\/NS20180201","article-title":"The dietary flavonoid isoliquiritigenin is a potent cytotoxin for human neuroblastoma cells","volume":"3","author":"Alshangiti","year":"2019","journal-title":"Neuron Signal."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13287-021-02231-x","article-title":"Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives","volume":"12","author":"Alves","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105206_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2008772118","article-title":"Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage","volume":"118","author":"Amen","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40360-020-00426-1","article-title":"Natural dietary compound naringin inhibits glioblastoma cancer neoangiogenesis","volume":"21","author":"Aroui","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","article-title":"Glioblastoma clinical trials: current landscape and opportunities for improvement","volume":"28","author":"Bagley","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105206_bib12","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/cancers13133304","article-title":"Fibroblast activation protein expressing mesenchymal cells promote glioblastoma angiogenesis","volume":"13","author":"Balaziova","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105206_bib13","article-title":"Nose-to-brain delivery of self-assembled curcumin-nanocochleates for glioblastoma treatment","volume":"104","author":"Bari","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/ijms23031353","article-title":"Wnt and PI3K\/Akt\/mTOR survival pathways as therapeutic targets in glioblastoma","volume":"23","author":"Barzegar Behrooz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105206_bib15","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.3390\/cancers13112765","article-title":"Current perspective on the natural compounds and drug delivery techniques in glioblastoma multiforme","volume":"13","author":"Behl","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12885-023-11792-4","article-title":"A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial","volume":"24","author":"Bhaskaran","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cancers13010047","article-title":"Recurrent glioblastoma: from molecular landscape to new treatment perspectives","volume":"13","author":"Birzu","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/cells10030621","article-title":"Cancer stem cells: significance in origin, pathogenesis and treatment of glioblastoma","volume":"10","author":"Biserova","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105206_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.695325","article-title":"Critical view of novel treatment strategies for glioblastoma: failure and success of resistance mechanisms by glioblastoma cells","volume":"9","author":"Burster","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/ijms26052192","article-title":"A review of FDA-approved multi-target angiogenesis drugs for brain tumor therapy","volume":"26","author":"Buzatu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105206_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/biomedicines8090310","article-title":"Investigating glioblastoma response to hypoxia","volume":"8","author":"Ch\u00e9deville","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12885-018-4267-z","article-title":"Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and-tolerant glioma cells","volume":"18","author":"Chio","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105206_bib24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/biology13110885","article-title":"IDH mutations in glioma: molecular, cellular, diagnostic, and clinical implications","volume":"13","author":"Choate","year":"2024","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/cancers14041092","article-title":"Glioblastoma microenvironment and cellular interactions","volume":"14","author":"Crivii","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib26","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2022.10.010","article-title":"Neuronal and tumourigenic boundaries of glioblastoma plasticity","volume":"9","author":"De Silva","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105206_bib28","doi-asserted-by":"crossref","DOI":"10.1039\/D4PM00263F","article-title":"Comprehensive review on glioblastoma: nanotechnology, immunotherapy and combined therapeutic approaches","author":"Dhiman","year":"2025","journal-title":"RSC Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cells13010044","article-title":"The biological and clinical role of the telomerase reverse transcriptase gene in glioblastoma: a potential therapeutic target?","volume":"13","author":"Di Nunno","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib30","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/s41467-023-36878-2","article-title":"Checkpoint kinase 1\/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade","volume":"14","author":"Dmello","year":"2023","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105206_bib31","doi-asserted-by":"crossref","first-page":"12608","DOI":"10.3390\/ijms222212608","article-title":"Hypoxia: the cornerstone of glioblastoma","volume":"22","author":"Dom\u00e8nech","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105206_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589929","article-title":"TERT\u2014regulation and roles in cancer formation","volume":"11","author":"Dratwa","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/pharmaceutics14051053","article-title":"Integrin-\u03b1v\u03b23 as a therapeutic target in glioblastoma: back to the future?","volume":"14","author":"Echavidre","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib34","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/ijms21030888","article-title":"Integrin signaling in glioma pathogenesis: from biology to therapy","volume":"21","author":"Ellert-Miklaszewska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib35","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/ijms25042316","article-title":"Epidermal growth factor receptor inhibitors in glioblastoma: Current status and future possibilities","volume":"25","author":"Ezzati","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7838583","article-title":"The role of natural products as inhibitors of JAK\/STAT signaling pathways in glioblastoma treatment","volume":"2022","author":"Fahmideh","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers11010022","article-title":"Honokiol eliminates glioma\/glioblastoma stem cell-like cells via JAK-STAT3 signaling and inhibits tumor progression by targeting epidermal growth factor receptor","volume":"11","author":"Fan","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib38","doi-asserted-by":"crossref","first-page":"830","DOI":"10.5966\/sctm.2016-0009","article-title":"\u03b2-Elemene selectively inhibits the proliferation of glioma stem-like cells through the downregulation of Notch1","volume":"6","author":"Feng","year":"2017","journal-title":"Stem Cells Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/s12967-024-05477-0","article-title":"From bench to bedside: the application of cannabidiol in glioma","volume":"22","author":"Feng","year":"2024","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/jpm11040258","article-title":"Diagnosis and management of glioblastoma: A comprehensive perspective","volume":"11","author":"Gilard","year":"2021","journal-title":"J. Pers. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105206_bib41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105206_bib42","article-title":"The TGF-\u00ce\u00b2 Family in Glioblastoma","volume":"25","author":"Golan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13020-024-00920-2","article-title":"Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK","volume":"19","author":"Guo","year":"2024","journal-title":"Chin. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105206_bib44","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/cells10082092","article-title":"GSK3 as a regulator of cytoskeleton architecture: Consequences for health and disease","volume":"10","author":"Hajka","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105206_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105206_bib46","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3389\/fonc.2020.01015","article-title":"PD-L1 expression in glioblastoma, the clinical and prognostic significance: a systematic literature review and meta-analysis","volume":"10","author":"Hao","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105206_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3892\/ijmm.2025.5564","article-title":"The regulatory role of CDK4\/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy","volume":"56","author":"He","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105206_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105206_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2095","article-title":"Liposomal curcumin and standard radiation and temozolomide for newly diagnosed high-grade gliomas: A phase 1\/2 study","author":"Holdhoff","year":"2025","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105206_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/cancers13020195","article-title":"Nanotechnology and nanocarrier-based drug delivery as the potential therapeutic strategy for glioblastoma multiforme: An update","volume":"13","author":"Hsu","year":"2021","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105206_bib51","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.3390\/cancers17203309","article-title":"The Urokinase-Type Plasminogen Activator Receptor (uPAR) as a Mediator of Physiological and Pathological Processes: Potential Therapeutic Strategies","volume":"17","author":"Iftikhar","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105206_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2018.03.006","article-title":"Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma","volume":"277","author":"Jhaveri","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105206_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.brainresbull.2020.08.019","article-title":"Tanshinone IIA suppresses lipopolysaccharide-induced neuroinflammatory responses through NF-\u03baB\/MAPKs signaling pathways in human U87 astrocytoma cells","volume":"164","author":"Jin","year":"2020","journal-title":"Brain Res. Bull."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105206_bib54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/biomedicines9070799","article-title":"IDH mutations in glioma: double-edged sword in clinical applications?","volume":"9","author":"Kayabolen","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105206_bib55","article-title":"Oridonin Enhances Radiotherapy Efficacy by Inducing Late-Stage Cell Death and G2\/M Arrest in U87MG Glioma Cells","author":"Khorramizadeh","year":"2025","journal-title":"Middle East J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105206_bib56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.procbio.2022.09.014","article-title":"Harmine inhibits proliferation and migration of glioblastoma via ERK signalling","volume":"122","author":"Kim","year":"2022","journal-title":"Process Biochem."},{"key":"10.1016\/j.critrevonc.2026.105206_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbrc.2021.06.025","article-title":"Antiangiogenic and antitumor potential of berbamine, a natural CaMKII\u03b3 inhibitor, against glioblastoma","volume":"566","author":"Kim","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105206_bib58","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.3390\/ijms19124048","article-title":"Pharmacological utilization of bergamottin, derived from grapefruits, in cancer prevention and therapy","volume":"19","author":"Ko","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105206_bib59","doi-asserted-by":"crossref","first-page":"13842","DOI":"10.18632\/oncotarget.7283","article-title":"Monoamine oxidase A (MAO A) inhibitors decrease glioma progression","volume":"7","author":"Kushal","year":"2016","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105206_bib60","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.21037\/atm-21-1836","article-title":"Liposomal honokiol inhibits glioblastoma growth through regulating macrophage polarization","volume":"9","author":"Li","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib61","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12935-021-02137-x","article-title":"Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression","volume":"21","author":"Li","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib62","first-page":"3333","article-title":"Oridonin inhibits growth and induces apoptosis of human neurocytoma cells via the Wnt\/\u03b2\u2011catenin pathway","volume":"16","author":"Liang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105206_bib63","article-title":"Saikosaponin D improves chemosensitivity of glioblastoma by reducing the its stemness maintenance","volume":"32","author":"Liang","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib64","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.phymed.2016.02.021","article-title":"Preclinical effects of honokiol on treating glioblastoma multiforme via G1 phase arrest and cell apoptosis","volume":"23","author":"Lin","year":"2016","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib65","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/ptr.7009","article-title":"Oridonin interrupts cellular bioenergetics to suppress glioma cell growth by down-regulating PCK2","volume":"35","author":"Lin","year":"2021","journal-title":"Phytother. Res."},{"key":"10.1016\/j.critrevonc.2026.105206_bib66","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.2147\/OTT.S242567","article-title":"Bufalin induces glioma cell death by apoptosis or necroptosis","author":"LingHu","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105206_bib67","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/JCMA.0000000000000552","article-title":"Overview of the molecular mechanisms of migration and invasion in glioblastoma multiforme","volume":"84","author":"Liu","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5489553","article-title":"Saikosaponin D inducing apoptosis and autophagy through the activation of endoplasmic reticulum stress in glioblastoma","volume":"2022","author":"Liu","year":"2022","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.critrevonc.2026.105206_bib69","article-title":"Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials","author":"Liu","year":"2025","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib70","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/life13040905","article-title":"Neural stem cells as potential glioblastoma cells of origin","volume":"13","author":"Loras","year":"2023","journal-title":"Life"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib71","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.3892\/ol.2017.5751","article-title":"Oridonin induces G2\/M cell cycle arrest and apoptosis via the PI3K\/Akt signaling pathway in hormone-independent prostate cancer cells","volume":"13","author":"Lu","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105206_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116458","article-title":"Juglone suppresses vasculogenic mimicry in glioma through inhibition of HuR-mediated VEGF-A expression","volume":"227","author":"Luo","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105206_bib73","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/cells14090675","article-title":"Targeting Glioma Stem Cells: Therapeutic Opportunities and Challenges","volume":"14","author":"Mahdi","year":"2025","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib74","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/onco4040024","article-title":"Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance","volume":"4","author":"Malhotra","year":"2024","journal-title":"Onco"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105206_bib75","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/cancers15061879","article-title":"The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment\u2014a systematic review","volume":"15","author":"Marino","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib76","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/cells10010184","article-title":"Hippo signaling pathway in gliomas","volume":"10","author":"Masliantsev","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib77","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/cancers14030498","article-title":"Therapeutic strategies targeting urokinase and its receptor in cancer","volume":"14","author":"Masucci","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105206_bib78","article-title":"Management of glioblastoma in elderly patients: A review of the literature","volume":"46","author":"Mazarakis","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105206_bib79","first-page":"1","article-title":"Negative trials over and over again: How can we do better?","author":"McFaline-Figueroa","year":"2023","journal-title":"Oxf. Univ. Press US"},{"key":"10.1016\/j.critrevonc.2026.105206_bib80","article-title":"Glioblastoma: clinical presentation, diagnosis, and management","volume":"374","author":"McKinnon","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2026.105206_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118340","article-title":"A brain-penetrant CDK4\/6 inhibitor-AU3-14 shows robust anti-tumor efficacy against glioblastoma","volume":"189","author":"Mekonnen","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105206_bib82","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105206_bib83","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105206_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e31678","article-title":"Nanoparticle-based delivery of harmine: A comprehensive study on synthesis, characterization, anticancer activity, angiogenesis and toxicity Evaluation","volume":"10","author":"Mohammadi","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2026.105206_bib85","article-title":"TERT promoter mutations in gliomas: molecular roles in tumorigenesis, metastasis, diagnosis, prognosis, therapeutic targeting, and drug resistance","author":"Murugan","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA)Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2026.105206_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1049888","article-title":"The function of natural compounds in important anticancer mechanisms","volume":"12","author":"Nan","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib87","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/ijms26031114","article-title":"Cellular and molecular mechanisms modulated by genistein in cancer","volume":"26","author":"Naponelli","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib88","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/diagnostics11030480","article-title":"Role of gelatinases MMP-2 and MMP-9 in healthy and complicated pregnancy and their future potential as preeclampsia biomarkers","volume":"11","author":"Nikolov","year":"2021","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib89","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma therapy: past, present and future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11060-019-03318-5","article-title":"The role of TP53 gain-of-function mutation in multifocal glioblastoma","volume":"147","author":"Olafson","year":"2020","journal-title":"J. NeuroOncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib91","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbrc.2020.01.148","article-title":"Indoleamine 2, 3-dioxygenase 1 is highly expressed in glioma stem cells","volume":"524","author":"Ozawa","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105206_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114491","article-title":"New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies","volume":"161","author":"Pandey","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105206_bib93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/diseases11020086","article-title":"Mechanical properties of glioblastoma: perspectives for YAP\/TAZ signaling pathway and beyond","volume":"11","author":"Pontes","year":"2023","journal-title":"Diseases"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib94","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies","volume":"24","author":"Pouyan","year":"2025","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resilience through chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41420-021-00456-6","article-title":"Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells","volume":"7","author":"Recasens","year":"2021","journal-title":"Cell death Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib97","first-page":"vdab163","article-title":"Expression of pluripotency-related genes in human glioblastoma","volume":"4","author":"Rios","year":"2022","journal-title":"NeuroOncol. Adv."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105206_bib98","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.3390\/ijms23137207","article-title":"Glioblastoma treatment: state-of-the-art and future perspectives","volume":"23","author":"Rodr\u00edguez-Camacho","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/futurepharmacol5010007","article-title":"Why do glioblastoma treatments fail?","volume":"5","author":"Ron\u010devi\u0107","year":"2025","journal-title":"Fut. Pharmacol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105206_bib100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/life14121523","article-title":"Impact of sex hormones on glioblastoma: sex-related differences and neuroradiological insights","volume":"14","author":"Rossi","year":"2024","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib101","article-title":"MGMT in TMZ-based glioma therapy: multifaceted insights and clinical trial perspectives","volume":"1871","author":"Shaw","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA)Mol Cell Res"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105206_bib102","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/nu15234854","article-title":"Inhibitory effects of urolithins, bioactive gut metabolites from natural polyphenols, against glioblastoma progression","volume":"15","author":"Shen","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.critrevonc.2026.105206_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149761","article-title":"Role of notch and its oncogenic signaling crosstalk in glioma and glioma stem cells","author":"Sidhu","year":"2025","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105206_bib105","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/genes14061276","article-title":"Suppression of NANOG expression reduces drug resistance of cancer stem cells in glioblastoma","volume":"14","author":"Smith","year":"2023","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105206_bib106","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.3390\/cancers15112883","article-title":"Mutant IDH in gliomas: role in cancer and treatment options","volume":"15","author":"Solomou","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib107","doi-asserted-by":"crossref","first-page":"567","DOI":"10.37349\/eds.2024.00062","article-title":"Multi-target and natural product-based multi-drug approach for anti-VEGF resistance in glioblastoma","volume":"2","author":"Soumya","year":"2024","journal-title":"Explor. Drug Sci."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105206_bib108","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.critrevonc.2026.105206_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123174","article-title":"Wnt signaling in the tumor microenvironment: a driver of brain tumor dynamics","volume":"358","author":"Suh","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105206_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112785","article-title":"Molecular biological mechanism of action in cancer therapies: Juglone and its derivatives, the future of development","volume":"148","author":"Tang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105206_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105821","article-title":"Identification of harmine and \u03b2-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies","volume":"162","author":"Tarpley","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib112","doi-asserted-by":"crossref","first-page":"21486","DOI":"10.1038\/s41598-024-72475-z","article-title":"Uncovering naringin\u2019s anticancer mechanisms in glioblastoma via molecular docking and network pharmacology approaches","volume":"14","author":"Tharamelveliyil Rajendran","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105206_bib113","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/jox14020036","article-title":"Traditional plant-derived compounds inhibit cell migration and induce novel cytoskeletal effects in glioblastoma cells","volume":"14","author":"Thompson","year":"2024","journal-title":"J. Xenobiotics"},{"key":"10.1016\/j.critrevonc.2026.105206_bib114","article-title":"Intranasal delivery of poly (d-glucosamine) encrusted self-assembled lipidic nanovesicles to enhanced brain uptake of thymoquinone for management of Glioblastoma Multiforme","volume":"90","author":"Trivedi","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105206_bib115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12032-018-1185-5","article-title":"Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme","volume":"35","author":"Tuncel","year":"2018","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105206_bib116","author":"Twelves","year":"2017","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105206_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.703761","article-title":"Natural small molecules targeting NF-\u03baB signaling in glioblastoma","volume":"12","author":"Uddin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105206_bib118","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.3390\/ijms232315189","article-title":"Many functions of telomerase components: certainties, doubts, and inconsistencies","volume":"23","author":"Udroiu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105206_bib119","unstructured":"Ullah, M.H., et al., Eco-friendly synthesis of silicon nanoparticles from banana peel extract and their in vitro and in vivo potential in glioblastoma treatment."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105206_bib120","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/ijms21061932","article-title":"Tumor cell invasion in glioblastoma","volume":"21","author":"Vollmann-Zwerenz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105206_bib121","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2016.05.045","article-title":"Quercetin-loaded freeze-dried nanomicelles: Improving absorption and anti-glioma efficiency in vitro and in vivo","volume":"235","author":"Wang","year":"2016","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib122","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3892\/or.2017.5878","article-title":"Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis","volume":"38","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib123","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2478\/acph-2020-0029","article-title":"Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K\/AKT\/mTOR signaling pathway","volume":"70","author":"Wang","year":"2020","journal-title":"Acta Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105206_bib124","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41422-020-00451-z","article-title":"Sequential fate-switches in stem-like cells drive the tumorigenic trajectory from human neural stem cells to malignant glioma","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib125","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3892\/ol.2022.13414","article-title":"Hedgehog signaling regulates the development and treatment of glioblastoma","volume":"24","author":"Wang","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105206_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109845","article-title":"Oridonin suppresses the growth of glioblastoma cells via inhibiting Hippo\/YAP axis","volume":"751","author":"Wang","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"issue":"02","key":"10.1016\/j.critrevonc.2026.105206_bib127","first-page":"115","article-title":"HIF-1\u03b1 facilitates glioma proliferation and invasion by activating pyroptosis signaling axis","volume":"10","author":"Wang","year":"2024","journal-title":"Chin. Neurosurg. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib128","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1038\/s41467-025-56930-7","article-title":"Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I\/II trial","volume":"16","author":"Weathers","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib129","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12967-024-05301-9","article-title":"The tumour microenvironment, treatment resistance and recurrence in glioblastoma","volume":"22","author":"White","year":"2024","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105206_bib130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3892\/mmr.2024.13344","article-title":"Current progress of anti\u2011PD\u20111\/PDL1 immunotherapy for glioblastoma","volume":"30","author":"Wu","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib131","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3892\/ol.2015.3888","article-title":"Resveratrol suppresses human glioblastoma cell migration and invasion via activation of RhoA\/ROCK signaling pathway","volume":"11","author":"Xiong","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105206_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1027577","article-title":"Irigenin inhibits glioblastoma progression through suppressing YAP\/\u03b2-catenin signaling","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105206_bib133","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105206_bib134","first-page":"669","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"NeurOncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105206_bib135","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/cancers15072116","article-title":"Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)","volume":"15","author":"Yalamarty","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105206_bib136","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12010-017-2491-7","article-title":"Isoliquiritigenin induces cytotoxicity in PC-12 cells in vitro","volume":"183","author":"Yang","year":"2017","journal-title":"Appl. Biochem. Biotechnol."},{"issue":"473","key":"10.1016\/j.critrevonc.2026.105206_bib137","doi-asserted-by":"crossref","first-page":"eaao5253","DOI":"10.1126\/scitranslmed.aao5253","article-title":"Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data","volume":"11","author":"Yang","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105206_bib138","first-page":"370","article-title":"\u03b2-elemene promotes the senescence of glioma cells through regulating YAP-CDK6 signaling","volume":"11","author":"Yang","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105206_bib139","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1038\/s41388-021-01721-9","article-title":"EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma","volume":"40","author":"Yeo","year":"2021","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/cells10030607","article-title":"The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy","volume":"10","author":"Yeo","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105206_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112922","article-title":"Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma","volume":"141","author":"Yin","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105206_bib142","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fphar.2020.00358","article-title":"Molecular targets for combined therapeutic strategies to limit glioblastoma cell migration and invasion","volume":"11","author":"Yool","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105206_bib143","doi-asserted-by":"crossref","first-page":"11309","DOI":"10.2147\/CMAR.S256347","article-title":"Tanshinone IIA suppresses glioma cell proliferation, migration and invasion both in vitro and in vivo partially through miR-16-5p\/talin-1 (TLN1) Axis","author":"You","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105206_bib144","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fonc.2019.01547","article-title":"O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy","volume":"9","author":"Yu","year":"2020","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105206_bib145","doi-asserted-by":"crossref","first-page":"e1460","DOI":"10.1002\/onco.13750","article-title":"Plasminogen activator urokinase receptor implies immunosuppressive features and acts as an unfavorable prognostic biomarker in glioma","volume":"26","author":"Zeng","year":"2021","journal-title":"oncologist"},{"key":"10.1016\/j.critrevonc.2026.105206_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.562798","article-title":"Current opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib147","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-020-00191-1","article-title":"Complex roles of cAMP\u2013PKA\u2013CREB signaling in cancer","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib148","first-page":"17","article-title":"Role of hypoxia inducible factor-1 in cancer stem cells","volume":"23","author":"Zhang","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105206_bib149","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/cancers15030830","article-title":"Exploring the past, present, and future of anti-angiogenic therapy in glioblastoma","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105206_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2021.147515","article-title":"Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation)","volume":"1766","author":"Zhou","year":"2021","journal-title":"Brain Res."},{"key":"10.1016\/j.critrevonc.2026.105206_bib151","article-title":"The global change of gene expression pattern caused by PTEN mutation affects the prognosis of glioblastoma","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105206_bib152","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12967-015-0727-2","article-title":"Reversion of malignant phenotypes of human glioblastoma cells by \u03b2-elemene through \u03b2-catenin-mediated regulation of stemness-, differentiation-and epithelial-to-mesenchymal transition-related molecules","volume":"13","author":"Zhu","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105206_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119112","article-title":"Harmine inhibits the proliferation and migration of glioblastoma cells via the FAK\/AKT pathway","volume":"270","author":"Zhu","year":"2021","journal-title":"Life Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:34:00Z","timestamp":1776101640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":153,"alternative-id":["S1040842826000934"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105206","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the molecular landscape of glioblastoma: Pathogenesis, therapeutic targets and bioactive interventions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105206"}}